BriaCell Therapeutics Corp. (BCTX)

NCM – Real vaqt narxi. Valyuta: USD

3.06

+0.09 (3.03%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

3.10

+0.04 (1.31%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

02.06.2026

BriaCell Therapeutics Announces Closing of Offering

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, were approximately $4.7 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

01.06.2026

BriaCell Presents Positive Clinical Data at ASCO 2026

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 study Biomarker analyses from the ongoing Phase 3 study further validates potential predictors of anti-cancer response initially reported in Phase 2 study 2026 ASCO Annual Meeting, May 29-June 2, 2026, at McCormick Place, Chicago, Illinois PHILADELPHIA and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces positive clinical data from three clinical data poster presentations at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612 ) and one poster highlighting further analyses of Phase 2 data.

31.05.2026

BriaCell Therapeutics Announces Pricing of Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

26.05.2026

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

22.05.2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29–June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC (ClinicalTrials.gov identifier: NCT06072612 ), and one poster highlighting further analyses of Phase 2 data.

15.05.2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. “Following the encouraging efficacy and tolerability data from BriaCell's Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian,” stated Dr. William V.

14.05.2026

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer.

Videolar

No Data

There is no data to display

BriaCell Therapeutics Corp. (BCTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Videolar

No Data

Press-relizlar

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Videolar

No Data

Press-relizlar

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Search stocks

BriaCell Therapeutics Corp. (BCTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Videolar

No Data

Press-relizlar

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Videolar

No Data

Press-relizlar

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer